Aptose Biosciences Inc. (APTO) Upgraded to “Hold” at Zacks Investment Research
According to Zacks, “Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “
A number of other analysts also recently weighed in on APTO. Roth Capital upgraded shares of Aptose Biosciences from a neutral rating to a buy rating and boosted their target price for the stock from $4.00 to $8.00 in a report on Monday, June 13th. Royal Bank Of Canada restated an outperform rating and issued a $23.00 target price on shares of Aptose Biosciences in a report on Monday, June 13th. Finally, RBC Capital Markets restated an outperform rating on shares of Aptose Biosciences in a report on Tuesday, September 13th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Aptose Biosciences currently has an average rating of Buy and a consensus target price of $12.30.
Shares of Aptose Biosciences (NASDAQ:APTO) opened at 2.3747 on Tuesday. Aptose Biosciences has a 12-month low of $1.92 and a 12-month high of $6.40. The company’s market cap is $30.61 million. The company has a 50 day moving average of $2.18 and a 200-day moving average of $2.47.
An institutional investor recently bought a new position in Aptose Biosciences stock. Bank of Montreal Can purchased a new position in Aptose Biosciences Inc. (NASDAQ:APTO) during the second quarter, according to its most recent filing with the SEC. The fund purchased 52,624 shares of the company’s stock, valued at approximately $128,000. Bank of Montreal Can owned about 0.43% of Aptose Biosciences as of its most recent SEC filing. Hedge funds and other institutional investors own 19.47% of the company’s stock.
Aptose Biosciences Company Profile
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.